Neither emulated analysis nor novel AI tools can overcome the limitations of insufficiently detailed information in population-based studies. Well-controlled prospective studies are needed to answer these questions.
JCO emulated trial, SABR vs surgery: surgery’s benefit was significant for all-cause mortality only; not lung cancer-specific mortality. That signals clinical imbalance, not inferior SABR: ECOG2 26% vs 7%, COPD 46% vs 26%. Salvage & nuanced treatment decision not in registry.View quoted post on X
